As the battle between Swiss major Novartis and biotech rival Kite Pharma heats up to be the first to market a CAR-T cancer med, the Big Pharma has been handed…

Allergan has wasted little time in testing out its new fatty liver candidate that it got in the potentially $1.7 billion buyout of Tobira last year as it pens…

Circassia has pulled the plug on its allergy programs after falling short in another study.

It doesn’t rain, but it pours in April for OncoMed: Last week, it had a double dose of bad news when it revealed that its Celgene-partnered lead asset…

Korean authorities say that Hanmi Pharmaceutical was too slow in revealing a side effect that later caused a fatality in the test of its lung cancer med…

Roche has posted an interim look at a phase 3 trial assessing the prophylactic use of its hemophilia A candidate emicizumab in kids.

Eli Lilly and Incyte were expecting an approval this weekend from the FDA for their blockbuster-in-waiting arthritis candidate baricitinib, but today announced…

A new survey of U.S. scientists, FDA researchers and biomedical clinicians has found that most are concerned over FDA Commissioner nominee Scott Gottlieb’s…

R&D